Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid

PLoS ONE

Volumn 13, Issue 7, 2018, Pages

  Yuille, Samantha ^a   Reichardt, Nicole ^a   Panda, Suchita ^a   Dunbar, Hayley ^a   Mulder, Imke E ^a  

^a 4DPharma Research Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; HEXANOIC ACID; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; PROBIOTIC AGENT; VALERIC ACID; HISTONE DEACETYLASE; N-PENTANOIC ACID;

ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; ENZYME INHIBITION; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE FLORA; MEGASPHAERA; MEGASPHAERA MASSILIENSIS; MICROBIAL COMMUNITY; MICROBIAL CONSORTIUM; NONHUMAN; CELL CULTURE TECHNIQUE; CULTURE MEDIUM; HT-29 CELL LINE; METABOLISM; PHYSIOLOGY;

BUTYRIC ACID; CELL CULTURE TECHNIQUES; CULTURE MEDIA; GASTROINTESTINAL MICROBIOME; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HT29 CELLS; HUMANS; MEGASPHAERA; PENTANOIC ACIDS;

EID: 85052211317     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0201073     Document Type: Article

References (46)

1. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016; 16(6):341–52. https://doi.org/10.1038/nri.2016.42 PMID: 27231050
2. Glauben R, Siegmund B. Inhibition of histone deacetylases in inflammatory bowel diseases. Mol Med. 2011; 17(5–6):426–33. https://doi.org/10.2119/molmed.2011.00069 PMID: 21365125
3. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F, et al. Histone Hyperacetylation Is Associated with Amelioration of Experimental Colitis in Mice. The Journal of Immunology. 2006; 176(8):5015–22. PMID: 16585598
4. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 2003; 94 (11):965–73. PMID: 14611673
5. Hegazi RA, Mady HH, Melhem MF, Sepulveda AR, Mohi M, Kandil HM. Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice. Inflamm Bowel Dis. 2003; 9(4):230–6. PMID: 12902846
6. Bultman SJ. Interplay between diet, gut microbiota, epigenetic events, and colorectal cancer. Mol Nutr Food Res. 2017; 61(1).
7. Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci. 2014; 34(46):15490–6. https://doi.org/10.1523/JNEUROSCI.3299-14.2014PMID: 25392516
8. Gulden E, Wong FS, Wen L. The gut microbiota and Type 1 Diabetes. Clin Immunol. 2015; 159(2):143–53. https://doi.org/10.1016/j.clim.2015.05.013 PMID: 26051037
9. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015; 528(7581):262–6. https://doi.org/10.1038/nature15766 PMID: 26633628
10. Zhang HL, Yu LX, Yang W, Tang L, Lin Y, Wu H, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol. 2012; 57(4):803–12. https://doi.org/10.1016/j.jhep.2012.06.011 PMID: 22727732
11. Yoon S, Eom GH. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J. 2016; 52(1):1–11. https://doi.org/10.4068/cmj.2016.52.1.1 PMID: 26865995
12. Ly NP, Litonjua A, Gold DR, Celedon JC. Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? J Allergy Clin Immunol. 2011; 127(5):1087–94; quiz 95–6. https://doi.org/10.1016/j.jaci.2011.02.015 PMID: 21419479
13. Usami M, Kishimoto K, Ohata A, Miyoshi M, Aoyama M, Fueda Y, et al. Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr Res. 2008; 28(5):321–8. https://doi.org/10.1016/j.nutres.2008.02.012 PMID: 19083427
14. Li Y, Innocentin S, Withers DR, Roberts NA, Gallagher AR, Grigorieva EF, et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell. 2011; 147(3):629–40. https://doi.org/10.1016/j.cell.2011.09.025 PMID: 21999944
15. Di Martino ML, Campilongo R, Casalino M, Micheli G, Colonna B, Prosseda G. Polyamines: emerging players in bacteria-host interactions. Int J Med Microbiol. 2013; 303(8):484–91. https://doi.org/10.1016/j.ijmm.2013.06.008 PMID: 23871215
16. Wang Q, McLoughlin RM, Cobb BA, Charrel-Dennis M, Zaleski KJ, Golenbock D, et al. A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J Exp Med. 2006; 203(13):2853–63. https://doi.org/10.1084/jem.20062008 PMID: 17178920
17. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017; 19(1):29–41. https://doi.org/10.1111/1462-2920.13589 PMID: 27928878
18. Steliou K, Boosalis MS, Perrine SP, Sangerman J, Faller DV. Butyrate histone deacetylase inhibitors. Biores Open Access. 2012; 1(4):192–8. https://doi.org/10.1089/biores.2012.0223 PMID: 23514803
19. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010; 28 (10):1057–68. https://doi.org/10.1038/nbt.1685 PMID: 20944598
20. Wang CC, Chen PS, Hsu CW, Wu SJ, Lin CT, Gean PW. Valproic acid mediates the synaptic excitatory/inhibitory balance through astrocytes—a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 37(1):111–20. https://doi.org/10.1016/j.pnpbp.2012.01.017 PMID: 22343008
21. Wang C, Henkes LM, Doughty LB, He M, Wang D, Meyer-Almes FJ, et al. Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities. J Nat Prod. 2011; 74(10):2031–8. https://doi.org/10.1021/np200324x PMID: 21793558
22. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011; 117(22):5827–34. https://doi.org/10.1182/blood-2010-10-312603 PMID: 21355097
23. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009; 27(32):5410–7. https://doi.org/10.1200/JCO.2008.21.6150 PMID: 19826128
24. Bultman SJ. Emerging roles of the microbiome in cancer. Carcinogenesis. 2014; 35(2):249–55. https://doi.org/10.1093/carcin/bgt392 PMID: 24302613
25. Fellows R, Denizot J, Stellato C, Cuomo A, Jain P, Stoyanova E, et al. Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases. Nat Commun. 2018; 9(1):105. https://doi.org/10.1038/s41467-017-02651-5 PMID: 29317660
26. Abel T, Zukin RS. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol. 2008; 8(1):57–64. https://doi.org/10.1016/j.coph.2007.12.002 PMID: 18206423
27. Kontopoulos E, Parvin JD, Feany MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet. 2006; 15(20):3012–23. https://doi.org/10.1093/hmg/ddl243PMID: 16959795
28. Bieliauskas AV, Pflum MK. Isoform-selective histone deacetylase inhibitors. Chem Soc Rev. 2008; 37(7):1402–13. https://doi.org/10.1039/b703830p PMID: 18568166
29. Johnsen LG, Skou PB, Khakimov B, Bro R. Gas chromatography—mass spectrometry data processing made easy. J Chromatogr A. 2017; 1503:57–64. https://doi.org/10.1016/j.chroma.2017.04.052 PMID: 28499599
30. Jacqueline C, Brazier L, Faugere D, Renaud F, Thomas F, Roche B. Can intestinal microbiota be associated with non-intestinal cancers? Sci Rep. 2017; 7(1):12722. https://doi.org/10.1038/s41598-017-11644-9 PMID: 28983086
31. Strati F, Cavalieri D, Albanese D, De Felice C, Donati C, Hayek J, et al. New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome. 2017; 5(1):24. https://doi.org/10.1186/s40168-017-0242-1 PMID: 28222761
32. Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome. 2016; 4(1):30. https://doi.org/10.1186/s40168-016-0171-4 PMID: 27338587
33. Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, et al. Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. PLoS One. 2015; 10(9):e0137429. https://doi.org/10.1371/journal.pone.0137429 PMID: 26367776
34. Minato T, Maeda T, Fujisawa Y, Tsuji H, Nomoto K, Ohno K, et al. Progression of Parkinson’s disease is associated with gut dysbiosis: Two-year follow-up study. PLoS One. 2017; 12(11):e0187307. https://doi.org/10.1371/journal.pone.0187307 PMID: 29091972
35. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010; 28(10):1069–78. https://doi.org/10.1038/nbt.1678 PMID: 20944599
36. Cousens LS, Gallwitz D, Alberts BM. Different accessibilities in chromatin to histone acetylase. J Biol Chem. 1979; 254(5):1716–23. PMID: 762168
37. Sivaprakasam S, Bhutia YD, Ramachandran S, Ganapathy V. Cell-Surface and Nuclear Receptors in the Colon as Targets for Bacterial Metabolites and Its Relevance to Colon Health. Nutrients. 2017; 9(8).
38. Braniste V, Al-Asmakh M, Kowal C, Anuar F, Abbaspour A, Toth M, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014; 6(263):263ra158.
39. Meng S, Wu James T., Archer Sonia Y., Hodin Richard A. Short-chain fatty acids and thyroid hormone interact in regulating enterocyte gene transcription. Surgery. 1999; 126(2).
40. Wilson AJ, Cheng YQ, Khabele D. Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy. J Ovarian Res. 2012; 5(1):12. https://doi.org/10.1186/1757-2215-5-12 PMID: 22531354
41. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124(1):30–9. https://doi.org/10.1172/JCI69738 PMID: 24382387
42. Angiolilli C, Kabala PA, Grabiec AM, Van Baarsen IM, Ferguson BS, Garcia S, et al. Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes. Ann Rheum Dis. 2017; 76(1):277–85. https://doi.org/10.1136/annrheumdis-2015-209064PMID: 27457515
43. Gonneaud A, Gagne JM, Turgeon N, Asselin C. The histone deacetylase Hdac1 regulates inflammatory signalling in intestinal epithelial cells. J Inflamm (Lond). 2014; 11(1):43.
44. Alenghat T, Osborne LC, Saenz SA, Kobuley D, Ziegler CG, Mullican SE, et al. Histone deacetylase 3 coordinates commensal-bacteria-dependent intestinal homeostasis. Nature. 2013; 504(7478):153–7. https://doi.org/10.1038/nature12687 PMID: 24185009
45. Felice C, Lewis A, Armuzzi A, Lindsay JO, Silver A. Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015; 41(1):26–38. https://doi.org/10.1111/apt.13008 PMID: 25367825
46. Tang Y, Lin YH, Ni HY, Dong J, Yuan HJ, Zhang Y, et al. Inhibiting Histone Deacetylase 2 (HDAC2) Promotes Functional Recovery From Stroke. J Am Heart Assoc. 2017; 6(10).